E
Etienne Dumont
Researcher at Hoffmann-La Roche
Publications - 9
Citations - 702
Etienne Dumont is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 647 citations.
Papers
More filters
Journal ArticleDOI
Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats
Cindy Fishman,Jessica Caverly Rae,L. M. Posobiec,Susan B. Laffan,Steven Lerman,Neil D. Pearson,Salima Janmohamed,Etienne Dumont,Deatra Nunn-Floyd,Dinesh Stanislaus +9 more
TL;DR: The absence of treatment-related clinical signs and arthropathy in juvenile rats provides evidence to support the potential future use of gepotidacin in children.
Journal ArticleDOI
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters
Aline Bergesch Barth,Caroline R Perry,Shaila S. Shabbir,Maciej J. Zamek-Gliszczynski,Sebin Thomas,Etienne Dumont,Darin Brimhall,Dung Nguyen,Meenakshi Srinivasan,Brandon Swift +9 more
TL;DR: Gepotidacin is a novel triazaacenaphthylene antibiotic in phase III development as mentioned in this paper , and two phase I studies were conducted in healthy participants to investigate clinical drug-drug interactions (DDIs).
Journal ArticleDOI
Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants
Aline Bergesch Barth,Mohammad Hossain,Caroline R Perry,Annette S. Gross,Hirofumi Ogura,Shaila S. Shabbir,Sebin Thomas,Etienne Dumont,Darin Brimhall,Meenakshi Srinivasan,Brandon Swift +10 more
TL;DR: In this paper , two clinical studies were conducted to assess the pharmacokinetics (PK) and interethnic comparisons of oral gepotidacin (freebase and to-be-marketed mesylate formulations) administered as single doses ranging from 1500 to 3000 mg in fed and fasted states, and as 2 × 3000 mg doses given 12 hours apart under fed conditions in healthy participants of Japanese ancestry.
Journal ArticleDOI
Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial
Rohit Loomba,Kris V. Kowdley,Jose Rodriguez,Linda Morrow,Philip D. Yin,Lakshmi Amaravadi,Brenda I. Jeglinski,Alicia Clawson,Swapan Chowdhury,Craig T. Basson,Etienne Dumont,Tatjana M. Odrljin +11 more